Please login to the form below

Not currently logged in

Pfizer and Astellas co-promote Caduet

Pfizer Japan and Astellas have agreed to co-promote a combination hypertension and hypercholesterolemia drug in Japan

The treatment, Caduet Combination Tablets, is an oral combination of Pfizer's hypertension treatment, Norvasc (amlodipine besylate) and hypercholesterolemia drug, Lipitor (atorvastatin calcium). The single tablet combination is expected to improve patient adherence.

Under the terms of the agreement (which lasts until July 2016), Pfizer will manufacture the combination treatment and be responsible for sales, while both companies will promote it.

The companies have worked together previously and co-promote Lipitor. Caduet Combination Tablets are approved in more than 70 countries/areas and will be available in Japan once listed on Japan's National Health Insurance drug price list.

26th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...